Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.

McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, Pellegrino M, Durruthy-Durruthy R, Watt CD, Asthana S, Lasater EA, DeFilippis R, Peretz CAC, McGary LHF, Deihimi S, Logan AC, Luger SM, Shah NP, Carroll M, Smith CC, Perl AE.

Cancer Discov. 2019 Aug;9(8):1050-1063. doi: 10.1158/2159-8290.CD-18-1453. Epub 2019 May 14.

PMID:
31088841
2.

Analysis of T cell receptor repertoire based on Vβ chain in patients with breast cancer.

Faghih Z, Deihimi S, Talei A, Ghaderi A, Erfani N.

Cancer Biomark. 2018;22(4):733-745. doi: 10.3233/CBM-181295.

PMID:
29945345
3.

Pharmacy student perspectives regarding curricular renewal with experiential alignment.

Nuffer W, Gilliam E, Thompson M, Deihimi S, Jordan K, Wienbar R, Vande Griend J.

Curr Pharm Teach Learn. 2017 Nov;9(6):1071-1079. doi: 10.1016/j.cptl.2017.07.020. Epub 2017 Oct 12.

PMID:
29233375
4.

Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.

Lev A, Deihimi S, Shagisultanova E, Xiu J, Lulla AR, Dicker DT, El-Deiry WS.

Cancer Biol Ther. 2017 Sep 2;18(9):694-704. doi: 10.1080/15384047.2017.1364323. Epub 2017 Sep 8.

5.

BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations.

Deihimi S, Lev A, Slifker M, Shagisultanova E, Xu Q, Jung K, Vijayvergia N, Ross EA, Xiu J, Swensen J, Gatalica Z, Andrake M, Dunbrack RL, El-Deiry WS.

Oncotarget. 2017 Jun 20;8(25):39945-39962. doi: 10.18632/oncotarget.18098.

Supplemental Content

Loading ...
Support Center